Shanghai, China

Lingjun Duan

USPTO Granted Patents = 2 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
2 patents (USPTO):

Title: Innovations of Lingjun Duan in Nitrogenous Heterocyclic Compounds

Introduction

Lingjun Duan is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of nitrogenous heterocyclic compounds. His work focuses on creating compounds that exhibit high inhibitory activity against specific cancer-related targets.

Latest Patents

Lingjun Duan holds 2 patents related to nitrogenous heterocyclic compounds. His latest patents include a nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application. The first patent describes a compound that demonstrates high inhibitory activity against ErbB2 tyrosine kinase, which is crucial in the treatment of human breast cancer cells BT-474 and human gastric cancer cells NCI-N87. This compound acts as an EGFR/ErbB2 double target inhibitor, providing a selective approach to cancer treatment. The second patent also focuses on a nitrogenous heterocyclic compound with similar properties, emphasizing its high selectivity and safety in targeting ErbB2.

Career Highlights

Throughout his career, Lingjun Duan has worked with notable companies, including Shanghai Pharmaceuticals Holding Co., Ltd. His experience in the pharmaceutical industry has allowed him to develop innovative solutions for cancer treatment. His research has contributed to the advancement of targeted therapies, enhancing the effectiveness and safety of cancer medications.

Collaborations

Lingjun Duan has collaborated with esteemed colleagues, including Guangxin Xia and Di Li. These partnerships have fostered a collaborative environment that promotes innovation and the sharing of ideas in the field of pharmaceutical research.

Conclusion

Lingjun Duan's work in the development of nitrogenous heterocyclic compounds showcases his commitment to advancing cancer treatment. His innovative patents and collaborations highlight the importance of targeted therapies in improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…